2020 Webinar Series

"CIOMS consensus report on Drug-Induced Liver Injury (DILI)"

7pm* to 8.30pm (Singapore Time), 20th July via Zoom

**Corresponds to 7am Eastern Standard Time (EST), 1pm Central European Time (CET) & 9pm Australian Central Standard Time (ACT)*

Time	Programme	Speakers
7.00pm	**Welcome and Introduction of Speakers** **Report of CIOMS DILI Working Group**	**Professor Mark I Avigan** Associate Director Critical Path Initiatives Office of Pharmacovigilance & Epidemiology Center for Drug Evaluation & Research U.S. Food and Drug Administration (USFDA)
	What CIOMS Is And What It Does : The DILI Initiative	**Professor Hervé Le Louët** President Council for International Organizations of Medical Sciences (CIOMS) Head, Vigilance Department Hôpital Universitaire Henri Mondor AP-HP Paris Créteil, France
	Principles in Detection, Characterization and Risk Assessment of DILI in Clinical Trials	**Dr Arie Regev** Chair, Liver and GI Safety Committee Chair, Safety Advisory Hub Global Patient Safety Eli Lilly and Company
	Liver Safety Biomarkers and **Herbal and Dietary Supplement Hepatotoxicity**	**Professor Raul J Andrade** Head, Department of Medicine University of Málaga Chief, Gastroenterology Service Virgen de la Victoria University Hospital Málaga (Spain)
	Best practices in post-market DILI risk assessment, risk minimization and communication	**Dr Walter Straus** Associate Vice-President and Chair Organ-Specific Safety Boards Merck Research Laboratories The United States of America MSD
	Questions	**Professor Einar S Björnsson** Chief of Internal Medicine National University Hospital of Iceland Reykjavik (Iceland)

	Panel Session and Q&A	**Moderator:** **Prof Mark I Avigan** USFDA **Panellists:** **Prof Hervé Le Louet** President Council for International Organizations of Medical Sciences (CIOMS) Head, Vigilance department Hôpital Universitaire Henri Mondor AP-HP Paris Créteil, France **Dr Arie Regev** Eli Lilly and Company **Prof Raúl J Andrade** University of Malaga **Prof Einar Stefán Björnsson** Chief Internal Medicine Landspitali University Hospital Reykjavik (Iceland)
	Summary and Key Takeaways **Closing Remarks**	**Professor Mark I Avigan** USFDA
8.30pm	**End of Webinar**	